NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
The company impresses investors, but money’s running short.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.